Medindia
Advertisement

Resolvyx Announces Positive Data from Phase 2 Trial of Resolvin RX-10045 for Dry Eye Syndrome

by Thilaka Ravi on August 24, 2009 at 6:28 PM

Resolvyx Announces Positive Data from Phase 2 Trial of Resolvin RX-10045 for Dry Eye Syndrome
Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome. In this 28-day, randomized, placebo-controlled, 232-patient trial, RX-10045 produced dose-dependent, statistically significant improvement on the primary endpoints for both the signs and symptoms of dry eye, and was generally shown to be safe and well tolerated. These Phase 2 results represent the first demonstration of clinical efficacy for the novel class of resolvin compounds and suggest that resolvins have the potential to treat a broad range of inflammatory diseases.

"There is an urgent need for new treatment options in dry eye and the results of this Phase 2 study are as strong as any I have seen," said Stephen Pflugfelder, MD, an expert in dry eye at Baylor College of Medicine. "Based both on these clinical results and on its unique mode of action, I am confident that RX-10045 can be an important new treatment modality for these patients."
Advertisement

The 28-day, randomized, multi-center, placebo-controlled study in 232 patients with moderate dry eye patients was designed to evaluate the safety, tolerability and efficacy of RX-10045 administered twice daily. The Phase 2 study examined three doses of RX-10045 and utilized a controlled adverse environment (CAE) to measure corneal staining in a stressful drying environment, as well as daily patient diaries using a standard visual analog scale to assess symptom improvement over the course of the study.

RX-10045 produced a significant dose-dependent improvement from baseline in symptoms recorded in daily patient diaries. The improvement was observed across all symptoms evaluated in the study, including dryness, stinging, burning, grittiness, ocular discomfort and the composite of each patient's most severe symptom (Worst Symptom Score). RX-10045 was superior to placebo on the primary symptomatic endpoint of Worst Symptom Score (p < 0.02), as well as on several individual symptoms. The onset of symptom relief occurred within the first week of treatment, and symptoms continued to improve over the course of the 28-day study, suggesting the potential for even greater benefit with longer treatment durations.
Advertisement

"I am very encouraged by the symptom relief achieved with RX-10045," said Ira Udell, M.D., Chairman of the Department of Ophthalmology at the North Shore-Long Island Jewish Health System and Professor of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine. "Symptomatic improvement is what really matters to patients."

RX-10045 also produced a 75% reduction from baseline in CAE-induced staining of the central cornea (p < 0.00001), the primary sign endpoint in the study. This improvement was greater than that observed for placebo, the difference approaching statistical significance (p = 0.11). RX-10045 also produced a significant improvement in CAE-induced staining in the inferior cornea and in the composite of central and inferior cornea, which also approached statistical significance over placebo (p = 0.09).

"We are very enthusiastic about the results of this Phase 2 study both as a demonstration of the potential of RX-10045 to treat dry eye patients and as the potential of the entire resolvin class to treat a range of inflammatory diseases," said Greg Weinhoff, Executive Chairman of Resolvyx. "The results of this study will help Resolvyx design the pivotal trials for RX-10045, which are currently targeted to begin in the first half of 2010."

Resolvyx is also currently conducting a Phase 1 study with a second resolvin, RX-10001, an orally-administered drug candidate for the treatment of systemic inflammatory diseases such as asthma, inflammatory bowel disease and other inflammatory diseases.



Source: Eurekalert
THK
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Lower Respiratory Tract Infections Linked to Obstructive Sleep Apnea in Children
Type 2 Diabetes can be Controlled by Unripen Green Jackfruit Flour
Covid Pandemic: How Parents can Help Kids Deal with Back-to-School Anxiety
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Eye Vision LASIK Surgery Facts Allergy Eye Drops Routine Eye Examination Quiz On Eye Donation Dry Eye Symptom Evaluation Clear the Blur-Tips to Boost Your Eye-Q Floppy Iris Syndrome Eyelid Bump 

Recommended Reading
Allergy
An allergy is a hypersensitive disorder of immune system. Substances that often cause allergic ......
Anatomy of the Eye - Animation
Interactive section of Medindia gives details regarding anatomy of the Eye...
Allergy Eye Drops
Eye allergies are treated with different types of eye drops such as lubricants, antihistamines, NSAI...
Clear the Blur-Tips to Boost Your Eye-Q
Eye problems may present as blurry vision or simply a minor headache, but they can affect your life ...
Dry Eye Symptom Evaluation
Dry eye may be due to a decrease in tear production, alteration of the tear consistency, or faster e...
Eyelid Bump
Our eyelids protect our eyes and keep them moist. Swelling of the eyelid may be localized due to cha...
Floppy Iris Syndrome
Floppy iris syndrome is associated with a high risk of complications following cataract surgery....
Routine Eye Examination
A comprehensive eye exam can take an hour or more, depending on the doctor and the number and comple...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use